Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Tablets × Dermatologic × Clear all

Phase

Status

Unknown 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6 Breast 5 Tumor-Agnostic 4 Thoracic 3 Other solid neoplasm 3 Lymphoid 3 Genitourinary 3 Myeloid 2 Head & Neck 2 Gastrointestinal 2 Plasma cell 1 Gynecologic 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Skin Neoplasms 1 Melanoma 1

Interventions

Ipilimumab 104 pembrolizumab 84 Nivolumab 83 aldesleukin 80 Cyclophosphamide 72 fludarabine phosphate 53 Interleukin-2 47 Dacarbazine 47 3-ingenyl angelate 37 Imiquimod 36 trametinib 32 Vemurafenib 32 sargramostim 31 incomplete Freund's adjuvant 31 Temozolomide 31 Radiotherapy 28 Peripheral Blood Stem Cell Transplantation 28 dabrafenib 26 fludarabine 25 Aminolevulinic Acid 25 Filgrastim 24 Bevacizumab 24 Photochemotherapy 22 Paclitaxel 22 Carboplatin 22 Whole-Body Irradiation 21 Melphalan 21 Interferon-alpha 21 Cisplatin 21 Sorafenib 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡